GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate ...

KRINTAFEL is an antimalarial indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection. (1) Limitations of Use. KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria.

GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in The New England Journal of Medicine.

2024年7月5日 · GSK plc (LSE/NYSE: GSK) and Medicines for Malaria Venture (MMV) today announce that the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria – tafenoquine, co-administered with chloroquine for radical cure, has now been launched in both Thailand and Brazil, in support of malaria elimination efforts.

Access - Approved Kozenis or Krintafel (Trademarks owned or licensed by GSK) GSK Relapse prevention Prevention of relapse for P. vivax (TPP-1)

2020年11月19日 · GSK and Medicines for Malaria Venture (MMV) today presented positive data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse (radical cure) of Plasmodium vivax (P. vivax) malaria in children and adolescents.

2017年11月28日 · GSK and MMV today announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients 16 years of age and older.

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for tafenoquine, an investigational medicine for the treatment and relapse prevention of …

2023年5月23日 · Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria. In areas of chloroquine resistance, artemisinin-based combination therapies are used to treat malaria.

GlaxoSmithKline (GSK) has gained the US Food and Drug Administration (FDA) priority review approval for its Krintafel (tafenoquine) to prevent relapse of malaria caused by Plasmodium vivax (P. vivax). Krintafel is considered as the first single-dose medicine approved to counter P. vivax malaria relapse. Credit: Andy Langager.